This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ewens, A. Articles by Ehrke, M. J. Search for Related Content PubMed PubMed Citation Articles by Ewens, A. Articles by Ehrke, M. J.

Doxorubicin plus Interleukin-2 Chemoimmunotherapy against Breast Cancer in Mice

Andrew Ewens, Liqun Luo, Erica Berleth, James Alderfer, Robert Wollman, Bilal Bin Hafeez, Peter Kanter, Enrico Mihich and M. Jane Ehrke

Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Enrico Mihich, Roswell Park Cancer Institute, 347 Grace Cancer Drug Center, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-3314; Fax: 716-845-3351; E-mail: enrico.mihich{at}roswellpark.org.

As recently characterized, following s.c. implantation into syngeneic C57BL/6 mice, E0771 tumor invades locally into dermal layers and peritoneum, metastasizes to the lung, and induces a nonspecific immunosuppression in the host. Using this breast medullar adenocarcinoma model, a therapy consisting of a single moderate dose of doxorubicin followed by twice daily moderate doses of interleukin-2 for 30 days was examined for efficacy and mechanism of action when given to animals with established disease. This combination treatment, but not combinants alone, resulted in tumor-free long-term survival of 40% of the mice without significant toxicity and 83% of survivors had immune memory specific for E0771 cells. Treatment also decreased immune suppression induced by E0771 tumor. Full response to treatment required functional CD8⁺ T cells, whereas depletion of natural killer cells caused only a reduction in response rate. A serum "biomarker" profile that correlated with, and seemed predictive of, response to treatment was identified by nuclear magnetic resonance–based metabonomic analysis. The efficacy of this nontoxic treatment and the potential to be able to predict which individual is responding to treatment are characteristics that make this chemoimmunotherapy attractive for clinical testing. (Cancer Res 2006; 66(10): 5419-26)

This article has been cited by other articles:

				M. Zheng, P. Lu, Y. Liu, J. Pease, J. Usuka, G. Liao, and G. Peltz 2D NMR metabonomic analysis: a novel method for automated peak alignment Bioinformatics, November 1, 2007; 23(21): 2926 - 2933. [Abstract] [Full Text] [PDF]